What is Scopio?
Scopio is at the forefront of transforming cell morphology analysis through a comprehensive suite of fully digital diagnostic applications and platforms. These solutions are designed to dramatically enhance clinical workflows, enabling faster, earlier, and more accurate disease detection and diagnosis. By overcoming the traditional tradeoff between field-of-view and resolution, Scopio empowers laboratories to assess and analyze cell morphology at an unprecedented scale and depth. The integration of high-resolution imaging with an AI-powered decision support system streamlines the diagnostic process, ensuring greater efficiency and consistency across the continuum of care. Scopio Labs' FDA-cleared and CE-marked Full-Field Peripheral Blood Smear application, alongside its ScopioVet veterinary application, are already in commercial use across the U.S. and Europe, demonstrating the company's market traction and technological viability.
How much funding has Scopio raised?
Scopio has raised a total of $118M across 3 funding rounds:
Series B
$16M
Series C
$50M
Series D
$52M
Series B (2020): $16M with participation from Aurum Ventures Private, OurCrowd, Olive Tree Ventures, and LR group
Series C (2022): $50M led by Ilex Medical, Bank Mizrahi-Tefahot, Aurum, and OurCrowd
Series D (2025): $52M supported by Viola Group and Fortissimo
Key Investors in Scopio
Viola Group
Viola Group is Israel's leading technology investment group, managing over $6 billion in assets and supporting Israeli entrepreneurs in building transformational technology companies through a multi-strategy investment approach. They cater to companies at various stages of development, particularly in the technology and FinTech sectors.
OurCrowd
OurCrowd is an investment platform founded in 2013 that enables accredited investors and institutions to invest in startups, early-stage companies, and venture funds, with a strong presence in Israel.
Ilex Medical
Ilex Medical has been providing groundbreaking solutions in medical instrumentation and diagnostics for five decades, focusing on advanced and innovative technologies that enhance public health and leading diagnostic projects with a vision for success.
What's next for Scopio?
With its recent major strategic investment, Scopio is poised for accelerated growth and further development of its AI-driven diagnostic solutions. The substantial capital infusion, totaling $118M with the latest round contributing $52M, will likely be directed towards expanding its commercial reach, enhancing its product offerings, and potentially exploring new diagnostic areas. The company's focus on improving diagnostic accuracy and efficiency positions it favorably within the rapidly evolving healthcare technology sector. Future endeavors may include further regulatory approvals, strategic partnerships, and scaling its operations to meet increasing global demand for advanced digital pathology tools.
See full Scopio company page
